Can intermittent dosing optimize prolonged linezolid treatment of difficult multidrug-resistant tuberculosis?

Antimicrob Agents Chemother. 2013 Jul;57(7):3445-9. doi: 10.1128/AAC.00388-13. Epub 2013 May 6.

Abstract

We evaluated treatment with linezolid, dosed at 800 mg once daily for 1 to 4 months as guided by sputum culture status and tolerance and then at 1,200 mg thrice weekly until ≥ 1 year after culture conversion, in addition to individually optimized regimens among 10 consecutive patients with extensively drug-resistant tuberculosis or fluoroquinolone-resistant multidrug-resistant tuberculosis. All achieved stable cure, with anemia corrected and neuropathy stabilized, ameliorated, or avoided after switching to intermittent dosing. Serum linezolid profiles appeared better optimized.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acetamides / administration & dosage*
  • Acetamides / therapeutic use
  • Adult
  • Antitubercular Agents / administration & dosage*
  • Antitubercular Agents / therapeutic use
  • Drug Administration Schedule
  • Female
  • Humans
  • Linezolid
  • Male
  • Middle Aged
  • Mycobacterium tuberculosis / drug effects*
  • Oxazolidinones / administration & dosage*
  • Oxazolidinones / therapeutic use
  • Sputum / microbiology
  • Treatment Outcome
  • Tuberculosis, Multidrug-Resistant / drug therapy*
  • Young Adult

Substances

  • Acetamides
  • Antitubercular Agents
  • Oxazolidinones
  • Linezolid